Physician profile
Mohammad J Javed
NPI 1497195481
$2,831.60
in general payments reported to CMS, 2019-2025
16 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $213 · 2022: $155 · 2023: $604 · 2024: $299 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129 · Travel and Lodging: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.42 |
| Travel and Lodging | $899.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $899.09 | 2025 | Deep Tms |
| Janssen Pharmaceuticals, INC | $444.23 | 2019-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $322.39 | 2020-2025 | Lybalvi, Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $227.91 | 2020-2025 | Ingrezza |
| Abbvie INC. | $227.56 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $224.86 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $115.12 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $106.82 | 2019 | |
| Supernus Pharmaceuticals, INC. | $62.61 | 2023-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $57.69 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $31.56 | 2024 | Cobenfy |
| Indivior INC. | $26.98 | 2023 | Sublocade |
| Bausch Health US, LLC | $21.90 | 2019 | |
| Owp Pharmaceuticals, INC. | $21.56 | 2024 | Subvenite |
| Biogen, INC. | $21.19 | 2025 | Zurzuvae |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $20.13 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Javed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.